Evidence map›Paper›PMID 31468307›Full record

ArticleDrug delivery and translational research2020

Shape mediated splenotropic delivery of buparvaquone loaded solid lipid nanoparticles.

Heena V Maithania, Bhabani S Mohanty, Pradip R Chaudhari, Abdul Samad, Padma V Devarajan

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Heena V MaithaniaDepartment of Pharmaceutical Sciences & Technology, Institute of Chemical Technology, Elite status and Centre of Excellence, Deemed University, Nathalal Parekh Marg, Matunga, Mumbai, 400019, India.
Bhabani S MohantyComparative Oncology Program and Small Animal Imaging Facility, Advanced Centre for Treatment, Education and Research in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.
Pradip R ChaudhariComparative Oncology Program and Small Animal Imaging Facility, Advanced Centre for Treatment, Education and Research in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India.
Abdul SamadBombay Veterinary College, Parel, Mumbai, 400012, India.
Padma V DevarajanDepartment of Pharmaceutical Sciences & Technology, Institute of Chemical Technology, Elite status and Centre of Excellence, Deemed University, Nathalal Parekh Marg, Matunga, Mumbai, 400019, India. pvdevarajan@gmail.com.ORCID 0000-0002-5701-3107

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Buparvaquone (BPQ)-loaded asymmetric solid lipid nanoparticles (SLN) prepared by a modified nanoprecipitation method were evaluated for splenotropic drug delivery. BPQ SLN exhibited an average particle size of 650.28 ± 6.75 nm with polydispersity index ≤ 0.3, entrapment efficiency of 96.57 ± 0.190%, and drug loading of 24.63 ± 0.042%. Scanning electron microscopy (SEM) revealed elongated particles with flattened and rounded edges. Aspect ratio, an important determinant of asymmetricity of the BPQ SLN, measured as the ratio of average length (1143 ± 0.083 nm) to width (419 ± 0.031 nm) was found to be 2.727 ± 0.19. The hemolytic potential of 10.86 ± 0.04% and good serum stability suggested feasibility for intravenous administration.

Indexed as

Administration, IntravenousAnimalsChemical PrecipitationDrug Delivery SystemsFemaleLipidsMiceMicroscopy, Electron, ScanningNanoparticlesNaphthoquinonesParticle SizeSpleenbuparvaquoneLipidsNaphthoquinonesAsymmetric shapeBuparvaquoneGamma scintigraphySolid lipid nanoparticlesSplenic uptakeSplenotropy

Identifiers

PMID31468307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.